Alkem Laboratories Ltd. News and Updates

Name: Latest research reports of Alkem Laboratories Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Alkem Laboratories Ltd.
Rating: 5
Author: Motilal Oswal

Keep track of all breaking news on Alkem Laboratories Ltd. from all sources in a single place.

Load latest

Alkem Laboratories Ltd.

09 Jun 2021

5479.50

0.13%

Buy Alkem; target of Rs 3730: Motilal Oswal

Moneycontrol

Motilal Oswal is bullish on Alkem recommended buy rating on the stock with a target price of Rs 3730 in its research report dated Jun 07, 2021.

Alkem Laboratories Ltd. is trading above all available SMAs

Alkem Laboratories Ltd.

07 Jun 2021

5479.50

0.13%

On growth path despite high base of past year

Buy: Alkem Laboratories Ltd.

Target

Motilal Oswal

It had a positive impact of higher offtake of COVID-19 associated drugs in the recent past. The reduction in COVID-19 cases, coinciding with seasonal change, bodes well for a pick-up in the performance of Acute therapies. Bunched-up ANDA launches over the next 12-15 months are expected to improve sales growth as well as profitability of the US business. We have tweaked our FY22E/FY23E EPS estimate by 2%/3% and continue to value ALKEM at 23x 12-months forward earnings to arrive at our TP of INR3,730. We remain positive on the back of robust growth in the DF segment and...

Alkem Laboratories Ltd. is trading above all available SMAs

Alkem Laboratories Ltd.

04 Jun 2021

5479.50

0.13%

Domestic markets, new product launches to drive FY22 earnings for Alkem

livemint

The mainstay India business continues to do well, with boost coming from covid-led sales. Analysts say that the company has seen a good pick-up in 1QFY22 sales of vitamins/minerals, antacids, antibiotics, pain relief medicines, among others

Alkem Laboratories L.. has an average target of 5296.00 from 2 brokers.

Alkem Laboratories Ltd.

26 May 2021

5479.50

0.13%

Alkem Labs sees huge sales momentum of anti-infectives in Q1FY22

Moneycontrol

Secondary infections due to bacteria and fungus have gained traction pushing up sales; healthy momentum in chronic therapies and increased usage of vitamins, nutrients and minerals act as growth triggers

Number of FII/FPI investors increased from 535 to 551 in Jun 2025 qtr.

Alkem Lab Standalone March 2021 Net Sales at Rs 1,917.47 crore, up 13.63% Y-o-Y

Moneycontrol | 26 May 2021

Alkem Laboratories Ltd.

26 May 2021

5479.50

0.13%

Alkem Labs (BUY): Poor US sales and inventory provision affect Q4

Buy: Alkem Laboratories Ltd.

Target

BOB Capital Markets Ltd.

Alkem Labs reported a below-expected Q4FY21 with +7%/4% YoY sales/EBITDA growth.

Number of FII/FPI investors increased from 535 to 551 in Jun 2025 qtr.

Alkem Laboratories Ltd.

20 May 2021

5479.50

0.13%

Alkem Laboratories Ltd - Ready for the next leap!

Buy: Alkem Laboratories Ltd.

Monarch Networth Capital Limited

ALKEM LABORATORIES LTD (Alkem) is a dominant Acute focused player in the IPM with leadership in the AntiInfectives. Its strong brands and penetration in the Acute side has led to its superior performance in the IPM. Chronic segment likely to double in size every 3 years on the back of Cardiac and Anti-diabetes. Higher profit contribution from chronic portfolio, improving MR productivity and rising scale in US generics will drive margin expansion of ~430bps over FY20-23E. Alkem's margins expansion visibility, rich return ratios and improving business profile merits a better multiple. We thus value Alkem at INR 4,000 on 17.5x EV/EVITDA on FY23E which gives an upside of 35% from the CMP. At current valuation of 13x EV/EBITDA and 18x PER on FY23E. Key risks include NPPA actions on key products, adverse USFDA regulatory actions and delay in biosimilars....

Alkem Laboratories L.. has an average target of 5296.00 from 2 brokers.

Alkem Laboratories Ltd.

24 Apr 2021

5479.50

0.13%

Why the stock of Alkem Labs is a good Buy'

Business Line

The stock is suitable for long-term investors, given multiple positives and reasonable valuation

Alkem Laboratories Ltd. is trading above all available SMAs

Alkem Laboratories Ltd.

12 Apr 2021

5479.50

0.13%

Pick of the Week - Alkem Laboratories Limited

Buy: Alkem Laboratories Ltd.

Edelweiss

Alkem is the seventh-largest branded pharma company in India.

Alkem Laboratories Ltd. is trading above all available SMAs

Alkem Laboratories Ltd.

12 Feb 2021

5479.50

0.13%

Buy Alkem Laboraties; target of Rs 3430: Motilal Oswal

Moneycontrol

Motilal Oswal is bullish on Alkem Laboraties has recommended buy rating on the stock with a target price of Rs 3430 in its research report dated February 06, 2021.

Alkem Laboratories Ltd. is trading above all available SMAs

Alkem Laboratories Ltd.

09 Feb 2021

5479.50

0.13%

Buy Alkem Laboratories; target of Rs 3242: Dolat Capital Market

Moneycontrol

Dolat Capital Market is bullish on Alkem Laboratories has recommended buy rating on the stock with a target price of Rs 3242 in its research report dated February 07, 2021.

Number of FII/FPI investors increased from 535 to 551 in Jun 2025 qtr.

Is Alkem Laboratories Ltd. worth buying?

139 Votes:

Buy 79.14%

Sell 14.39%

Hold 6.47%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Sell SEE REPORTS >

pdf